Search

Displaying results 4001 - 4010 of 10000 in total
  1. Drug

    Ubiquinol

    go.drugbank.com/drugs/DB11340
    ApprovedInvestigational

    Ubiquinol (CoQH2) is a reduced form of coenzyme Q10 (CoQ10) that acts as an active antioxidant that prevents the initiation and propagation of lipid peroxidation in biological membranes and human low-density … not classified as a vitamin because it is synthesized by humans.

  2. Drug

    Fluoride ion F-18

    go.drugbank.com/drugs/DB09398
    ApprovedInvestigational

    Sodium Fluoride F 18 Injection is a positron emitting radiopharmaceutical, no-carrier added. … Increased deposition around joints can occur in arthritis and following trauma and increased deposition in bone has been noted around fracture sites, in osteomyelitis, fibrous dysplasia, spondylitis tuberculosa

  3. Drug

    Pentagastrin

    go.drugbank.com/drugs/DB00183
    Approved

    It has also been used as a diagnostic aid. … A synthetic pentapeptide that mimics the actions of endogenous gastrin when given parenterally. It works by stimulating the secretion of gastric acid, pepsin, and intrinsic factor.

  4. Drug

    Idarubicin

    go.drugbank.com/drugs/DB01177
    ApprovedInvestigational

    An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.

    Categories: Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic IndexSynonyms: (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydronaphthacen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
  5. Drug

    KW-7158

    go.drugbank.com/drugs/DB05498
    Experimental

    The therapeutic effects of KW-7158 in overactive bladder may be due to the activation of A-type K(+) channels which regulate afferent neuron excitability and firing properties in the dorsal root ganglion … KW-7158 is a tricyclic compound with a non-cholingergic mechanism of action for the treatment of "urinary urgency," "frequent urination" and "urinary incontinence" associated with bladder overactivity

  6. Drug

    Pyrvinium

    go.drugbank.com/drugs/DB06816
    ApprovedInvestigationalWithdrawn

    Pyrvinium is an anthelmintic effective for pinworms. Several forms of pyrvinium have been prepared with variable counter anions, such as halides, tosylate, triflate and pamoate.

  7. Drug

    Dengue virus serotype 2

    go.drugbank.com/drugs/DB22665
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … Dengue virus serotype 2 is a serotype of _Orthoflavivirus denguei_ known to cause dengue fever.

  8. Drug

    Dengue virus serotype 3

    go.drugbank.com/drugs/DB22666
    Approved

    [L53368] Qdenga was approved for use in the European Union in December 2022.[L53373] … Dengue virus serotype 3 is a serotype of _Orthoflavivirus denguei_ known to cause dengue fever.

  9. Drug

    ANA971

    go.drugbank.com/drugs/DB05127
    Experimental

    ANA971, an orally administered prodrug of isatoribine. Isatoribine is a nucleoside analog in development for the treatment of chronic hepatitis C virus (HCV) infection. … ANA971 is a prodrug designed to improve the oral bioavailability of isatoribine.

  10. Drug

    Pazopanib

    go.drugbank.com/drugs/DB06589
    ApprovedInvestigational

    Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index